Wellbutrin

Esophageal Cancer

Lisa Sanderson Cox, PhDPhase 4 / ApprovedDormant

B

60/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 56/ 100
Competitive Position: 65/ 100

Competitive context

109 Active assets in the Esophageal Cancer cohort.

Asset / Sponsor	Phase	Rating
FLUOROURACILUM Merck Sharp & Dohme LLC	Phase 4	BB
Cyclophosphamide Sutro Biopharma, Inc.	Phase 3	B
Pembrolizumab Essen Biotech	Phase 3	B
Epirubicin Sutro Biopharma, Inc.	Phase 3	B
Eloxatin Shenyang Sunshine Pharmaceutical Co., LTD.	Phase 2	B

View all 50 →

Same molecule, other indications

Wellbutrin is also rated in:

Smoking CessationDormant

A

Indicative ·

82 / 100

DysthymiaDormant

BBB

Indicative ·

73 / 100

depressive disorderDormant

BB

Indicative ·

71 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.